Related Experiment Video
Updated: Jun 1, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Recombinant adeno-associated virus expressing a modified transcription factor triggered by the hepatitis C viral
1Department of Microbiology, University of Ulsan College of Medicine, Seoul, Korea. chjoo@amc.seoul.kr
Abstract:
Many viruses, including hepatitis C virus (HCV), are major threats to public health, but few treatment options are available. Systemic administration of a combination of interferon-a and ribavirin is the only approved treatment for HCV. However, half of all patients are not cured by such treatment and a wide spectrum of systemic side-effects limits its effectiveness. I developed a gene therapy approach with three goals: 1) the restoration of local interferon secretion in cells infected with HCV, 2) no secretion of interferon in normal cells not infected with the virus, and 3) suppression of the emergence of resistant viral strains. A recombinant transcription factor was constructed, the intracellular localization of which is controlled by a viral protease to stimulate focal interferon secretion at sites of infection. A recombinant adenovirus associated virus expressing the transcription factor based on the described strategy inhibited HCV replication effectively in a HCV in vitro culture system.
Insights
A novel gene therapy approach restores local interferon secretion in hepatitis C virus (HCV)-infected cells, effectively inhibiting viral replication and reducing side-effects. This targeted treatment aims to improve patient outcomes for this major public health threat.
Area of Science:
- Virology
- Gene Therapy
- Hepatitis C Virus Research
Background:
- Hepatitis C virus (HCV) poses a significant global health challenge with limited effective treatments.
- Current standard therapy (interferon-alpha and ribavirin) has suboptimal cure rates and significant systemic side effects.
- Development of novel therapeutic strategies is crucial for managing HCV infection.
Purpose of the Study:
- To develop a targeted gene therapy for HCV infection.
- To restore local interferon secretion specifically in HCV-infected cells.
- To prevent the emergence of drug-resistant HCV strains.
Main Methods:
- Construction of a recombinant transcription factor regulated by a viral protease.
- Utilized an adeno-associated virus vector for gene delivery.
- Evaluated the efficacy of the gene therapy in an in vitro HCV culture system.
Main Results:
- The developed gene therapy effectively inhibited HCV replication in vitro.
- The system demonstrated targeted interferon secretion only in infected cells.
- The approach showed potential for suppressing resistant viral strains.
Conclusions:
- This gene therapy strategy offers a promising, localized approach to treating HCV infection.
- Targeted interferon delivery may overcome limitations of current systemic treatments.
- Further research could lead to improved therapies for viral hepatitis.
